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Abstract
Extracellular vesicles (EVs), including exosomes and
microvesicles, carry a variety of bio-macromolecules,
including mRNA, microRNA, other non-coding RNAs,
proteins and lipids. EVs have emerged as a promising,
minimally invasive (liquid biopsies) and novel source of
material for molecular diagnostics, and may provide a
surrogate to tissue biopsy-based biomarkers for a variety
of diseases. Although EVs can be easily identified and
collected from biological fluids using commercial kits,
further research and proper validation is needed in order
for them to be useful in the clinical setting. Currently,
several EV-based research and diagnostic companies have
developed research-based kits and are in the process of
working with clinical laboratories to develop and validate
EV-based assays for a variety of diseases. The successful
clinical application of EV-based diagnostic assays will
require close collaboration between industry, academia,
regulatory agencies and access to patient samples. We
expect that international, integrative and interdisciplinary
translational research teams, along with the emergence of
FDA-approved platforms, will set the framework for EV-
based diagnostics. We recognize that the EV field offers
new promise for personalized/precision medicine and
targeted treatment in a variety of diseases.
A short course was held as a four-session webinar series in
September and October 2014, presented by pioneers and
experts in the EV domain, covering a broad range of topics
from an overview of the field to its applications, and the
current state and challenges of the commercialization of
EVs for research and an introduction to the clinic. It was
concluded with a panel discussion on the regulatory
aspects and funding opportunities in this field. A summary
of the short course is presented as a meeting dispatch.
Keywords extracellular vesicles, exosomes, short course,
liquid biopsies, therapeutics, funding, clinical trials
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1. Introduction
EVs are small vesicles, containing diverse “nucleic acids”
and protein cargo that are spontaneously secreted by all
cells and found in abundance in all human body fluids.
Depending upon the cell or tissue of origin, many different
roles and functions have been attributed to EVs, for
example: the eradication of obsolete molecules, the facili‐
tation of the immune response, antigen presentation,
programmed cell death, angiogenesis, inflammation,
coagulation, the dissemination of oncogenes from tumour
cells and the spread of pathogens such as prions and
viruses from one cell to another. Importantly, EVs deliver
macromolecular messages that enable cell-to-cell commu‐
nication and signalling. The short course, EVs: The Transi‐
tion from Tissue to Liquid Biopsies was sponsored by the
BioPharma Research Council and was held as a four-
session series in October and November 2014. The goal of
the short course was to provide, at an introductory level,
an exchange between researchers from academia and
industry in the characterization of applications of EVs in
clinical and translational research and, eventually, clinical
practice. The EV topics included an overview of its appli‐
cations, the commercial aspects, therapeutic hurdles and
funding opportunities.
2. Session 1 – September 11, 2014
2.1 Overview of Extracellular Vesicles by Jan Lötvall, MD, PhD
The first session presented by Jan Lötvall, provided an
overview of EVs (their function and role in medicine and
therapy). Jan started by describing and providing a history
of EVs. EVs are membrane vesicles with a lipid bilayer that
have surface molecules present on the surface containing
cytoplasmic molecules, which can vary in size, with the
smaller EVs ranging from 40-150 nm, which have a
regulatory function. EVs were first described in 1983 as
debris by two groups, Harding et al. and Pan et al.,
discussing the transferrin receptor sent out from the cells
becoming erythrocytes. Earlier studies, in 1967 and 1977,
discussed platelet dust and prostasomes, respectively. Jan
continued to discuss where EVs are found, what they
contain and what can they do in disease. The three major
groups of EVs, even though there are many names used in
the literature, are: 1) microvesicles budding off the surface
of the cells which are released, containing surface receptors,
and attaching to another cell (surface-to-surface interac‐
tion) or even being taken up by another cell; 2) exosomes,
which are smaller EVs, are produced by multivesicular
endosomes, contain different types of cargo, and are taken
up by another cell (recipient cell); and 3) larger vesicles
produced by programmed cell death, the apoptotic bodies.
These are important in cell-to-cell communication.
Jan further discussed how the production of EVs is a
conserved process, as seen in bacteria, plants and parasites,
which is not specific in human cells. A recent paper in
Science reported bacterial vesicles found in marine ecosys‐
tems (the ocean) as they relate to ocean-depth. They
demonstrated the transfer of carbon when giving these
vesicles to another bacterium to sustain life. In another
example, Jan discussed a controversial issue, the presence
of rice miRNA in the circulation of Chinese people, where
intact miRNA molecules from the rice are present in the
EVs, whereby harbouring the rice cargo. Lastly, two
abstracts presented at the ISEV meeting discussed the
presence of EVs in beer, especially in unfiltered beer, and
how they are ingested by humans.
What are the functions of EVs? EVs have several functions,
including surface-to-surface interactions (antigen presen‐
tation), first described in 1996. Another function is the
shuttling of proteins, RNA and lipids between cells. The
presence of nucleotides in EVs was described in the late
1990s, considering the packaging of DNA and RNA in
apoptotic bodies during apoptosis. In 2006, a study
demonstrated that vesicles greater than 100 nm provided
evidence that mRNA and protein can be delivered from one
cell to another. In 2007, Jan’s group showed the presence of
mRNA and miRNA in smaller EVs - 40-50 nm - shuttling
materials between cells. To prove that the RNA was
functional, they took mouse exosomes with mRNA to
human mast cells, translating proteins in human cells. They
found a number of proteins from exosomes, and a number
of proteins that were present as mRNA and not present at
proteins in exosomes, suggesting that mouse RNA can be
translated to protein in the recipient cell. There was also a
presence of functional miRNA.
How do you test whether the RNA is functional? Jan’s
group exposed exosomes to oxidative stress and placed
EVs on top of cells, placing them under stress again –
mediating a protective message under stress.
Where do you find extracellular RNA? They are found in
all the body fluids, like blood, plasma, saliva, breast milk
and urine. The communication of RNA containing exo‐
somes can be made by kissing or may be by breast milk
(mother to child communication – uptake by macrophages
– immune tolerance and T-regulatory cells).
EVs are present in fetal bovine serum (FBS). In cell culture
experiments, FBS is often used to supplement the cell
culture medium as a nutrient, but it is important to know
that the FBS also contains significant quantities of EVs. Jan’s
group showed how RNA-containing EVs in FBS can be
removed to almost 95% of cases with an 18-hours centrifu‐
gation protocol, and this approach strongly reduces the
functionality of FBS vesicles in relation to epithelial cell
migration.
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What can EVs do in medicine? They can promote and
attenuate disease. Jan described the presence of bacterial
EVs (outer membrane) released from pseudomonas
aeruginosa, where his group isolated the EVs from the cell
to look to see whether they induce pseudomonas aerugi‐
nosa related pathologies/symptoms. In another example,
outer membrane EVs from pseudomonas aeruginosa
showed strong inflammation (travel through the body
quickly by EVs) without any bacteria at all; clearly, EVs are
very potent, inducing symptoms. Clearly, all bacterially
(both pathogenic and non-pathogenic) released EVs are
distributed throughout the body, inducing an inflammato‐
ry process. EVs have also been found in the peripheral
blood of sepsis patients.
In the cancer field, Jan discussed a few examples of the role
of EVs in tumours and cancers. Tumours contain cancer
cells, fibroblasts, immune cells and inflammatory cells, but
EVs play a role in influencing these cells in the microenvir‐
onment. Jan further discusses the role of EVs secreted
under hypoxia and how they enhance the invasiveness of
prostate cancer cells - cells secreting EVs from the center of
the tumour. Another study discussed how EVs from triple-
negative breast cancer cells can transfer phenotypic traits.
Lastly, Jan discussed a recent study which showed the
reprogramming of patient-derived adipose stem cells by
prostate cancer cell-associated EVs that actually produce
tumours.
Jan stated there are many subsets of EVs. His group showed
that apoptotic bodies, microvesicles and exosomes contain
fundamentally different RNA profiles, arguing that
microvesicles isolated from cell cultures often do not
contain considerable amounts of RNA. The rRNA was
primarily found in apoptotic bodies, which should be
considered when the functionality of RNA in different
vesicles is studied.
Exosomes as therapy? Jan discussed a paper published by
a group from Tokyo who systemically injected exosomes
targeted to EGFR to deliver anti-tumour miRNA to breast
cancer cells, suggesting that you can target to tumours
partly by functional RNA.
In summary, Jan concluded the following:
1. Exosomes and other EV contain RNA
2. The RNA can be shuttled between cells
3. Mediate biological messages
4. Circulating esRNA can be biomarkers
5. Exosomes and other EVs can deliver therapy
6. Possibilities for treating cancer and inflammatory
diseases
In addition, he invited everyone to the upcoming ISEV
meeting held in Washington DC that will take place during
April 23-26, 2015, at the Bethesda North Marriot Hotel.
3. Session 2 – September 18, 2014
3.1 Clinical Diagnostic Applications of Extracellular Vesicles by
Johan Skog, PhD
The second session, by Johan Skog, discussed the clinical
diagnostic applications of EVs, including sample collection
and processing approaches, and platform applications,
including exosome RNA mutation analysis and expression
profiling. Johan started off by describing an overview of
EVs. Various imaging technologies like electron microsco‐
py (EM) and scanning EM can be used to characterize EVs,
and it has been shown that EVs are heterogeneous in nature
and that they vary in size (30 nm to greater than 1,000 nm).
Cryo-EM show that EVs are a double-lipid membrane, but
interestingly EVs are single-lipid bi-layers and one can see
vesicles within vesicles. The contents of the EVs are
interesting - they contain mRNA, miRNA, non-coding
RNA and a variety of proteins – a good platform for
biomarkers. The package of EVs is about 10 kb of RNA, not
the entire transcriptome. You will find one or a few
transcripts per vesicle – carrying different messages.
Johan discussed the extraction of nucleic acids from
biofluid such as plasma. Using the exosome platform
enables the sub-fractionation of RNA from different
cellular processes by way of total exosome extraction (ultra-
centrifugation, filter purification, etc.) and affinity purifi‐
cation (magnetic beads, microfluidics, etc.). In using whole-
plasma extraction, there is a problem in that there is no
selectivity from the sub-fractions (RNA is acquired from all
kinds of components) and there is a limit in the efficiency
of the RNA extraction with higher volumes due to RNase
activity. Johan showed that exosomal isolation demon‐
strates the good quality/yield of intact RNA and 18S and
28S ribosomal RNA peaks compared to direct extraction.
Johan stated that the pre-processing of one’s samples is a
critical step, like avoiding cell carry-over. He emphasized
that the need for standardized SOPs for the collection and
pre-processing of your samples is important. When
isolating nucleic acid isolation, you need to know whether
you are extracting DNA or RNA, since small amounts of
RNA are easily be biased by DNA. It is important to have
controls in your extraction method. Johan uses the ExoRNA
isolation method because it is scalable. Most blood collec‐
tion tubes are compatible with extraction methods, but
have different biases. Johan emphasized using controls/
standards and the same collection protocol for all patients.
Exosome RNA is stable once isolated, even under freeze-
thaw cycles. Johan mentioned that there are multiple
sources of RNA in biofluids and that exosome RNA is not
the same as the direct precipitation of RNA. By conducting
the lysis on the filter using the exoRNeasy kit, one can
capture the RNA, even the flow-through (miRNA),
directly. High volumes of samples are needed for high-
sensitivity applications, like looking for oncogenes and
tumour mutations.
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Exosome RNA profiling can be used to monitor treatment
responses - Johan found unique expression changes in the
responder group when compared to the non-responder
group and when validated by single-plex qPCR validation.
Johan concluded there are benefits in measuring tumour
mutations in biofluids because there is less risk for the
patient than invasive biopsy, it is cheaper than surgery, and
it can obtain multiple samples over time to track changes
longitudinally (although there are still challenges in
isolations and in detecting rare tumour transcripts).
4. Session 3 – September 25, 2014
4.1 Commercialization Aspects of Extracellular Vesicles by
Alexander “Sasha” Vlassov, PhD
The third session on the commercialization aspects of EVs
was presented by Alexander “Sasha” Vlassov. His session
discussed how the spectrum of current scientific interest in
exosomes is wide, ranging from studying their functions
and pathways, to utilizing them in the development of
diagnostics and therapeutics. For example, Exosome
Diagnostics developed a biofluid-based molecular diagnos‐
tic test for use in personalized medicine. The company's
proprietary exosome technology makes use of this natural
enrichment to achieve high sensitivity and specificity for
rare gene transcripts, as well as the expression of genes
responsible for cancers and other diseases. Caris Life
Sciences developed Carisome – an innovative, proprietary
and versatile testing technology that has the potential to
reveal critical information about disease at its earliest
stages, from a simple blood test. Currently being developed
for a number of types of cancers, including prostate, breast,
lung and colorectal cancers, the technology has the poten‐
tial to provide diagnostic, prognostic and theranostic
information for patients. Exosome Sciences developed
exosome-based solutions to improve the identification and
monitoring of acute and chronic conditions. Candidate
products are focused on diagnostic advancements in the
fields of oncology, infectious disease and brain injury.
Exosomics Sienna performs applied research and R&D
activities in the field of exosome-associated biomarkers,
with a specific focus on the development and validation of
proprietary immunometric multiplex assays for non-
invasive cancer diagnostics and monitoring and point-of-
care devices for cancer screening.
In speaking about therapeutic applications, Sasha men‐
tioned how exosomes have tremendous potential as
vesicles for the in vivo delivery of various therapeutic
cargos. For instance, one group reported the successful use
of exosomes for the delivery of short interfering RNA
(siRNA) to the brain in mice. Targeting was achieved by
engineering dendritic cells to express Lamp2b, a membrane
protein found in exosomes, fused to the neuron-specific
RVG peptide3. Loaded exosomes were purified from
conditioned culture media of these cells with synthetic
siRNA using electroporation and intravenously injected
using RVG-p3-tagged exosomes that delivered siRNA
specifically to neurons, microglia and oligodendrocytes in
the brain, resulting in a specific gene's knockdown.
A completely different therapeutic approach was proposed
by Aethlon Medical. A few years ago, it was reported that
tumour-secreted exosomes actually suppress the immune
response to the cancer. Aethlon Medical developed the
Hemopurifier® medical device to selectively remove the
tumour-secreted exosomes from the circulatory system.
Their postulate is that this will restore the immune system
of the cancer patients. The technology uses a large format
flow-through canister that can work in an apheresis mode.
Proprietary lectins attached to the canister-bed matrix act
as unique affinity-capture moieties for exosomes, targeting
mannose residues on their surface.
Taking into account that the number of applications and
commercial opportunities is rapidly increasing, exosomes
are very small and complex entities - there is a growing
need for quick and easy methods for both the isolation of
exosomes and the analysis of the containing cargo. Life
Technologies (now part of Thermo Fisher Scientific)
developed a complete exosome workflow solution: (i) the
fast and efficient recovery of exosomes from serum,
plasma, urine, cerebrospinal fluid, amniotic fluid, ascitic
fluid, milk, saliva and cell media using total exosome
isolation reagents; (ii) the extraction of their “cargo” with
total exosome RNA and a protein isolation kit; (iii) the
characterization of exosomal RNA content using the Ion
Torrent Proton sequencing and qRT-PCR with TaqMan®
assays. A number of additional kits and reagents were
released recently, allowing the versatile and advanced
analysis of exosomes and EVs (www.lifetechnologies.com/
exosomes). For example, Dynabeads with conjugated anti-
CD63, CD81, CD9, EpCAM antibodies enable the isolation
of exosomal subpopulations.
The continuous development of next-generation tools is
crucial in furthering our understanding of exosomes and
expanding the range of their practical applications. More‐
over, based on the recent reports, this goes beyond mam‐
malian systems to plants, bacteria and - possibly - other
kingdoms, where EVs have many undiscovered roles and
many exciting practical uses including, for example, food
and cosmetic industries.
5. Session 4 Part 1– October 2, 2014
5.1 Extracellular Vesicles: Therapeutic Hurdles by Eva Rohde,
MD
Part one of the fourth session was a presentation on the
therapeutic hurdles in the EV ecosystem by Eva Rohde. Eva
expressed the increasing interest in the putative therapeutic
potency of human cell-derived EVs. EV-based therapeutics
are biologicals that may be categorized as ‘high risk
medicinal products’ due to currently unknown mecha‐
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nisms of action (MoAs). She stressed the challenges in EV
characterization and the design of preclinical studies as
well as aspects of pharmaceutical engineering which have
to be addressed to overcome the hurdles on the way to
clinical application. A lack of safety data as well as partic‐
ular knowledge about the nature of the therapeutic target
or further biomedical uncertainties (as, for example, the
most representative animal models for EV-based therapies)
may setback the translational process. Unsurprisingly, data
from clinical trials (CTs) testing EV-based therapeutics are
scarce. From this point of view, we are not yet perfectly
prepared for the clinical testing of EV-based therapeutics.
Nevertheless, study protocols evaluating the therapeutic
potency of EVs will emerge and broad clinical testing will
hopefully start in the foreseeable future. To accelerate the
developmental process bringing EV-based therapies into
clinics, a close collaboration between researchers and
public health authorities is urgently required.
6. Session 4 Part 2– October 2, 2014
6.1 Funding opportunities for Extracellular Vesicle Research by
Angel Ayuso Sacido, PhD
The second part of the session was a discussion on the
funding opportunities for EV research by Angel Ayuso
Sacido. Angel primarily focused on the funding opportu‐
nities within the European Union based on his experience.
He provided an overview of the structure of the European
Parliament, the Council and the Commission. The Europe‐
an Union is based on a 10-year milestone process. The
previous programme, entitled the “Lisbon Strategy”, from
2000-2010, was based on growth and jobs, whereas the
Horizon 2020 is very broad, whereby 3% of the EU’s GDP
is focused on research and development. Angel suggested
three cores - industrial leadership, societal challenges and
excellent science - in which EV research could fall under.
Angel also mentioned partnership opportunities, “Looking
for Partners” using a matchmaking tool, “Fit for Health”
and “Funding for Networks” by “EraNets”, a networking
mechanism of national and regional programmes, and
“COST”, the European Cooperation in Science and Tech‐
nology programme.
7. Conclusion
Based on the session presentations, it was evident that the
field of EV research is quickly evolving and that it continues
to advance in all facets of science. Overall, the short course
fulfilled its goal of providing a balanced forum of relevant
content from researchers from both academia and industry.
The webinar presentations are available on the BioPharma
Research Council website (http://www.biopharmare‐
searchcouncil.org/webinar-short-course-in-the-exosome).
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